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Pulmonary hypertension (PH) is a known complication of HCM and is a strong predictor of
mortality. We aim to investigate the relationship between microvascular dysfunction mea-
sured by quantitative PET and PH in HCM patients.
Methods
Eighty-nine symptomatic HCM patients were included in the study. Each patient underwent
two 20-min 13N-NH3 dynamic PET scans for rest and stress conditions, respectively. A 2-tis-
sue irreversible compartmental model was used to fit the segments time activity curves for
estimating segmental and global myocardial blood flow (MBF) and myocardial flow reserve
(MFR). Echocardiographic derived PASP was utilized to estimate PH.
Results
Patients were categorized into two groups across PASP: PH (PASP > 36 mmHg) and no-
PH (PASP� 36 mmHg). patients with PH had larger left atrium, ratio of higher inflow early
diastole (E) and atrial contraction (A) waves, E/A, and ratio of inflow and peak early diastolic
waves, E/e’, significantly reduced global stress MBF (1.85 ± 0.52 vs. 2.13 ± 0.56 ml/min/g;
p = 0.024) and MFR (2.21 ± 0.57 vs. 2.62 ± 0.75; p = 0.005), while the MBFs at rest between
the two groups were similar. There were significant negative correlations between global
stress MBF/MFR and PASP (stress MBF: r = -0.23, p = 0.03; MFR: r = -0.32, p = 0.002); for
regional MBF and MFR measurements, the highest linear correlation coefficients were
observed in the septal wall (stress MBF: r = -0.27, p = 0.01; MFR: r = -0.31, p = 0.003).
Global MFR was identified to be independent predictor for PH in multivariate regression
analysis.
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Conclusion
Echocardiography-derived PASP is negatively correlated with global MFR measured by
13N-NH3 dynamic PET. Global MFR is suggested to be an index of PH in HCM patients.
Introduction
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, char-
acterized by cardiac hypertrophy and phenotypic heterogeneity [1, 2]. Although much atten-
tion has focused on the left-sided pathophysiology, alterations in pulmonary hemodynamics
may also be evident. Patients with HCM may develop to pulmonary hypertension (PH) due to
elevated left-sided diastolic pressures, secondary to diastolic dysfunction, and in a minority of
cases to the primary pulmonary vascular resistance [3]. A few studies have identified that PH
in HCM is associated with a poor prognosis even with mild elevations in pulmonary pressures
[3–5]. However, there is considerable variability in the clinical course of HCM patients, addi-
tional modalities which could identify patients at risk for PH and adverse outcomes might be
useful in the clinical evaluation of HCM patients.
Coronary microvascular dysfunction is an central physiopathology in HCM, and has major
prognostic implications as well [6]. Growing evidence suggests that the assessment of micro-
vascular function detected by quantitative positron emission tomography (PET) could play an
important role in the evaluation and management of myocardial ischemia in patients with
HCM [7]. Accordingly, impaired hyperemic myocardial blood flow (MBF) and myocardial
flow reserve (MFR) were regarded as equivalent to the microvascular dysfunction [8]. To date,
it remains unknown whether microvascular function and PH are associated. In the present
study, we used 13N-NH3 dynamic PET imaging to explore the possible quantitative relation-




This project was reviewed and approved by the John Hopkins Institutional Review Board (No.
00029377), All procedures and methods were performed in accordance with the updated
guidelines and regulations. All patients provided consent to use clinical data for research pur-
poses, and written informed consents were obtained from all participants. The retrospective
study enrolled 118 patients with HCM at Johns Hopkins Hospital, Baltimore, USA, from June
2011 to December 2015 referred to cardiac PET/CT. The clinical diagnosis of HCM was based
on 2-dimesional echocardiographic evidence of LV hypertrophy (maximal wall thickness�15
mm) in the absence of other cardiac or systemic disease such as obstructive coronary artery
disease (> 50% diameter stenosis) by invasive coronary angiography or computed tomography
angiography, hypertension, sarcoidosis capable of producing hypertrophy [1, 2]. All patients
underwent comprehensive echocardiographic evaluation and 13N-NH3 dynamic PET imaging
within a 1-month period. 29 patients were excluded from this analysis because of moderate or
severe valval heart disease, severe lung disease and unavailable measurement of peak tricuspid
regurgitation gradients, as well as patients whose PET images were missing or uninterpretable
owing to poor image quality.
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Echocardiography
Two-dimensional Doppler echocardiographic studies were performed using a GE Vivid 7 or
Ezuochuang-9 ultrasound machine (GE Ultrasound, Milwaukee, WI) on each patient. Echo-
cardiographic assessments were based on the current guideline [9]. Peak instantaneous LV
outflow gradient was estimated with continuous wave Doppler at rest and after exercise to
elicit latent obstruction. Rest obstruction was defined as gradient� 30 mmHg at rest, latent
obstruction as gradient < 30 mmHg at rest, but gradient� 30 mmHg on provocation, and no
obstruction as gradient < 30 mmHg at rest and on provocation. Inflow early diastole (E) and
atrial contraction (A) waves were assessed for the E/A ratio. The peak early diastolic wave (e’)
was used to calculate the E/e´ ratio. The PASP was obtained by addition of estimated right
atrial pressure based on inferior vena cava size and collapsibility and trans-tricuspid gradient
calculated from the modified Bernoulli equation [4 times the velocity (in m/s) of tricuspid
regurgitation jet (TRV) square] [10]. Pulmonary stenosis or right ventricular outfiow tract
obstruction were excluded. PH was identified as PASP > 36 mmHg and classified as mild
(PASP 37~50 mmHg) and moderate or severe (PASP> 50 mmHg) [4, 11].
PET/CT acquisition
All patients underwent cardiac PET/CT scanning using a GE 64-slice Discovery Rx VCT PET/
CT system (GE Healthcare, Waukesha, Wisconsin). Patients were positioned with the assis-
tance of a computed tomographic (CT) scout, a low-dose CT scan (120 kv, 30 mA) was per-
formed for attenuation correction of PET emission data. Subsequently, 20-min dynamic PET
images were acquired using a same-day rest/stress protocol [12, 13] as follows: approximately
370 MBq 13N-NH3 was injected intravenously as a bolus (using a power injector as constant
rate of 1200 ml/h), and a list-mode dynamic PET scan was obtained over 20 minutes. Approxi-
mately 60 minutes after injection of the rest dose, Regadenoson (Lexiscan, Gilead Sciences
Inc., Foster City, California) (0.4 mg/5 ml) was administered for vasodilator stress, and the
stress PET scan was started about 30 sec after Regadenoson administration. Heart rate, blood
pressure, and a 12-lead electrocardiogram were recorded before, during, and after completion
of the stress protocol.
The attenuation- and decay-corrected 36-frame (20×6, 5×12, 4×30, 5×60, 2×300 seconds)
dynamic PET images (volume size:128×128×47, and voxel size: 3.27×3.27×3.27 mm in x, y, z
direction) and gated PET images (8 bins per cardiac cycle, volume size:128×128×47, voxel size:
3.27×3.27×3.27 mm) were reconstructed using an iterative ordered-subset expectation-maxi-
mization (OS-EM) algorithm (2 iterations, 21 subsets) with post-processing filtering (Butter-
worth, order 0.5 cycles/cm).
MBF quantification
All reconstructed dynamic PET images were transferred to a workstation for image processing
and quantification using the PCARDP tool (PMOD Technologies, Zurich, Switzerland, ver-
sion 3.4). The images were reoriented along the heart axis, and segmented into the AHA
17-segments within the detected endo- and epicardial borders [14]. A 2-tissue irreversible
compartment model (2TCM) with four parameters (F, k2, k3, Vb) (15) was employed for fitting
the 17-segments tracer time-activity curve (TAC). Volume of interests (VOIs) were manually
drawn in the mitral of LV and in the right ventricle on PET images. The LV TACs and the
average of LV and RV TACs were used as input function and blood volume correction, respec-
tively. Our in-house software were used for model fitting [15]. The septal, anterior, lateral,
inferior and global flow (S1 Table) and MFR were calculated from the 17 segmental MBFs and
MFRs. Coronary vascular resistance was calculated as the mean arterial blood pressure divided
PET-measured myocardial flow reserve and echocardiography-estimated pulmonary artery systolic pressure
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by MBF at rest (maximal coronary vascular resistance) and stress (minimal coronary vascular
resistance) as follows:
CVR ¼ 0:33� ðð2� diastolic pressureÞ þ systolic pressureÞ=MBF
Gated PET evaluation
Stress and rest LV ejection fraction (LVEF), LV end-diastolic volumes (LVEDV) and LV end-
systolic volumes (ESV) were automatically calculated from gated datasets by using QGS pack-
age (Cedars Sinai, Los Angeles, California). The LVEF reserve was computed as stress LVEF
minus rest LVEF. A drop larger than– 5 LVEF units was considered abnormal LVEF reserve as
previously reported [16].
Statistical analysis
Simple statistics including mean, standard deviation (SD), and proportions were calculated for
continuous variables and categorical variables, respectively. The comparison between groups
of continuous samples was performed with a Student’s t test, Mann–Whitney U test and one-
way ANOVA depending on the nature of data. Categorical variables between groups were
compared using the χ2 test. Spearman’ correlation coefficients were calculated for potential
correlation between MBF/MFR and other variables. Univariable and multivariable linear
regression analyses were performed to study the independent contributions of various param-
eters on PASP. A p< 0.05 was required for statistical significance. The IBM SPSS 23.0 software
(IBM Corp, Somers, NY) was used for all statistical analysis.
Results
Clinical and echocardiographic features
Overall, the PH (PASP> 36 mmHg) was observed in 31 (35%) patients. Moderate or severe
PH (PASP> 50 mmHg) was presented in 5 (6%) patients. Clinical and echocardiographic fea-
tures of the patients with PH versus patients without PH are summarized in Table 1. There is
no significant difference of age, gender, BMI, cardiovascular risk factors and symptoms. Non-
invasive parameters of diastolic function including E/A ratio and medial E/e’ ratio were signifi-
cantly worse in the PH group versus no-PH group (p< 0.01; p< 0.05, respectively). In addi-
tion, PH group had more increased left atrial size (4.4 ± 0.9 vs. 4.0 ± 0.6 cm, p<0.05) than no-
PH group.
Regional and global MBF
The last 18-min mean stress/rest PET images with representative global MBF and MFRs for
HCM patients with and without PH are demonstrated by Fig 1A-1 and 1B-1. The apical-lateral
kinetic modeling results for the two typical HCM patients are illustrated by Fig 1A-2 and 1B-2.
The model parameters of F, k2, k3 and Vb estimated from 17-segmental TACs based kinetic
modeling for all patients are summarized in the S1 Table. Simple statistics of global MBF and
MFR estimates for PH and no-PH HCM patients are included in Table 2. Patients with PH
had evidence of significantly lower global stress MBF (1.85 ± 0.52 vs. 2.13 ± 0.56 ml/min/g;
p< 0.05) and MFR (2.21 ± 0.57 vs. 2.62 ± 0.75; p< 0.01), while a higher global minimal CVR
(52.31 ± 13.35 vs.44.18 ± 12.51 ml/min/g/mmHg; p< 0.01). Similarly, there were much more
patients being classified as having abnormal stress MBF or MFR in group of PH than those
patients in group of no-PH (p< 0.05 and p< 0.01 for MBF� 1.8 ml/min/g and MFR� 2.5,
PET-measured myocardial flow reserve and echocardiography-estimated pulmonary artery systolic pressure
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respectively. S2 Table). On the other hand, when compared the regional parameters between
these two groups, septal and lateral MBFs at stress, as well as each regional MFR were signifi-
cantly depressed in PH patients (Fig 2).
PET-derived LVEF
At rest, PET-derived LVEF was similar between the two groups (p> 0.05). During vasodilator
stress, patients with PH exhibited impaired LVEF compared to the patients without PH
(46 ± 12 vs. 52 ± 12%; p< 0.05). As a consequence, group of PH yielded lower LVEF reserve
values (-8 ± 6 vs. -5 ± 5%; p< 0.01) and high prevalence of abnormal LVEF reserve (64% vs.
40%; p< 0.05) as above defined (S3 Table).
LVOT obstruction
In the study, 32 (36%) patients were classified as no-obstructive HCM, 32 (36%) had latent
obstruction and 25 (28%) had rest obstruction. Obstructive HCM patients were more likely to









Age, years 52±15 52±13 52±17 0.893
Sex, male, n(%) 45(51) 31(53) 14(45) 0.456
BMI, kg/m2 28.5±4.7 28.6±4.8 28.4±4.5 0.850
NYHA Class III/IV, n(%) 51(58) 32(56) 19(61) 0.640
Dyspnea, n(%) 64(73) 39(68) 25(81) 0.219
Risk factors
Hypertension, n(%) 45(50) 29(50) 16(52) 0.885
Dyslipidemia, n(%) 48(54) 30(52) 18(58) 0.568
Diabetes mellitus, n(%) 12(13) 9(15) 3(10) 0.442
Smoking, n(%) 30(34) 20(34) 10(32) 0.832
Medications
β-Blockers 65(73) 41(71) 24(77) 0.495
Calcium channel blockers 28(31) 19(33) 9(29) 0.718
Diuretics 16(18) 10(17) 6(19) 0.805
Disopyramide 3(3) 0(0) 3(10) 0.016
Echocardiographic parameters
Maximal LV thickness, cm 2.0±0.5 2.0±0.4 2.1±0.5 0.128
Rest LVOT gradient, mmHg 29±29 27±28 33±32 0.359
Provoked LVOT gradient, mmHg 68±56 67±59 72±51 0.513
LVEF(%) 67±7 67±6 67±8 0.662
Moderate/severe MR, n(%) 16(19) 8(14) 8(27) 0.160
LAD, cm 4.1±0.7 4.0±0.6 4.4±0.9 0.015
E/A ratio 1.5±0.7 1.3±0.6 1.8±0.9 0.004
E/e’ ratio 18.3±8.7 16.9 ±7.1 21.5±10.5 0.021
Data are expressed as mean ± standard deviation or number of the patients(percentage).
PH:pulmonary hypertension; BMI: body mass index; NYHA: New York Heart Association; LVOT: left ventricular outflow tract; LVEF: left ventricular ejection fraction;
MR: mitral regurgitation; LAD: left atrial diameter; E/A:ratio of peak early diastolic velocity(E)/peak atrial filling velocity(A); E/e’: ratio of peak early diastolic velocity
(E) /peak early diastolic velocity of the septal mitral annulus (e’).
https://doi.org/10.1371/journal.pone.0212573.t001
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have higher E/e’ ratio; Otherwise, there was no significant difference in stress MBF, MFR, min-
imal CVR and PASP among the 3 groups, as depicted in Table 3.
Correlations
On the basis of findings that the echocardiographic parameters including PASP, LAD, E/A
and E/e’ ratio were significantly different between patients with and without PH, we further
investigate their correlations with the global MBF/MFR. The results showed that global stress
MBF was negatively correlated with PASP values (r = -0.23; p< 0.05) and E/A ratio (r = -0.24;
p< 0.05) but not LAD and E/e’ ratio; Similarly, global MFR was only negatively related to
PASP values (r = -0.32; p< 0.01). On the other hand, the global MBFs at rest did not correlate
with PASP (p> 0.05). Furthermore, the correlation between regional stress MBF/ MFR and
Fig 1. Representative cases of HCM with or without PH. (A1, B1): patient A is a 56-year-old female with normal
PASP showing no evidence of vasodilator stress-induced myocardial ischemia; patient B is a 37-year-old female with
elevated PASP revealing global myocardial ischemia but most severe in mid to apical regions of lateral and anterior
walls; Lines from left to right: short axial slice; vertical axial slice; horizontal axial slice; (A2, B2): Time-activity curves at
stress and rest. Dashed line: arterial blood; Hollow dots: myocardial time-activity curve of apical-lateral segment
measured by PET; Solid line: myocardial time-activity curve predicted by the model.
https://doi.org/10.1371/journal.pone.0212573.g001








SBP, mmHg 130±19 128±20 135±18 0.103
DBP, mmHg 75±12 74±12 78±11 0.145
Global stress MBF, ml/min/g 2.03±0.56 2.13±0.56 1.85±0.52 0.012
Global rest MBF, ml/min/g 0.85±0.20 0.84±0.17 0.86±0.24 0.952
Global MFR, unitless 2.48±0.71 2.62±0.75 2.21±0.57 0.005
Maximal CVR, ml/min/g/mmHg 110.78±30.27 110.74±26.35 110.87±37.09 0.586
Minimal CVR, ml/min/g /mmHg 46.98±13.31 44.18±12.51 52.31±13.35 0.001
Data are expressed as mean ± standard deviation.
PH:pulmonary hypertension; SBP: systolic blood pressure; DBP: diastolic blood pressure; MBF: myocardial blood flow; MFR: myocardial flow reserve; CVR: coronary
vascular resistance.
https://doi.org/10.1371/journal.pone.0212573.t002
PET-measured myocardial flow reserve and echocardiography-estimated pulmonary artery systolic pressure
PLOS ONE | https://doi.org/10.1371/journal.pone.0212573 March 20, 2019 6 / 13
PASP showed that the coefficients in septal wall were the highest (stress MBF: r = -0.27,
p< 0.05; MFR: r = -0.32, p< 0.01, respectively) among all regional walls (Fig 3).
Univariate and multivariate regression analysis were further performed to identify the pre-
dictive factors for PH (all HCM patients). In univariable analysis, a significant correlation was
found between PASP and global stress MBF, MFR, minimal CVR, LAD, E/A ratio and E/e0
Fig 2. Comparison of global and regional MBF/ MFR between HCM patients with and without PH. A: stress MBF;
B: rest MBF; C: MFR. �p<0.05, ��p<0.01 for comparison between PH versus no PH.
https://doi.org/10.1371/journal.pone.0212573.g002
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ratio. On separate step-wise forward multiple linear regression, only global MFR(β = -0.35;
p< 0.01), E/A ratio(β = 0.35; p< 0.01) and systolic blood pressure(β = 0.29; p< 0.01) were
the independent predictors for PH as showed in Table 4.
Table 3. Characteristics of HCM patients with and without obstruction.
Characteristics Non-obstructive HCM (n = 32) Latent obstructive HCM (n = 32) Obstructive HCM (n = 25) p-value
Global stress MBF, ml/min/g 2.01±0.58 2.11±0.57 1.95±0.52 0.642
Global MFR, unitless 2.40±0.61 2.60±0.84 2.42±0.60 0.449
Minimal CVR, ml/min/g /mmHg 47.70±12.77 46.36±13.07 46.82±14.77 0.615
Rest LVOT gradient, mmHg 29±29 27±28 33±32 <0.001
Provoked LVOT gradient, mmHg 68±56 67±59 72±51 <0.001
LAD, cm 4.1±0.9 4.0±05 4.3±0.7 0.234
E/A ratio 1.7±1.0 1.4±0.6 1.4±0.5 0.382
E/e’ ratio 15.7±7.3 18.6 ±7.0 22.1±10.9 0.009
PASP, mmHg 34±10 34±8 37±10 0.456
Data are expressed as mean ± standard deviation.
MBF: myocardial blood flow; MFR: myocardial flow reserve; CVR: coronary vascular resistance; LVOT: left ventricular outflow tract; LAD: left atrial diameter; E/A:ratio
of peak early diastolic velocity(E)/peak atrial filling velocity(A); E/e’: ratio of peak early diastolic velocity (E) /peak early diastolic velocity of the septal mitral annulus
(e’); PASP: pulmonary artery systolic pressure
https://doi.org/10.1371/journal.pone.0212573.t003
Fig 3. Correlation between PASP and PET parameters in the total HCM cohort. (A1,A2):correlation between PASP and global/regional stress
MBF; (B1,B2): correlation between PASP and global/regional rest MBF; (C1,C2): correlation between PASP and global/regional MFR.
https://doi.org/10.1371/journal.pone.0212573.g003
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Discussion
Our study demonstrates a link between echocardiography-estimated pulmonary pressure and
the PET-measured MBF/MFR in HCM. These patients showed significantly more severe
impairment of global and regional stress MBF and MFR than patients without PH. The study
also indicates that global MFR which is independently determined for the change in PASP,
indicating that impaired MFR is associated with PH in HCM patients.
Although invasive right heart catheterization remains the gold standard for assessment of
pulmonary pressures, echocardiographic-derived measures of PASP was highly correlated to
right heart catheterization in patients with left heart pathology [9, 17, 18], thereby validating
echocardiography as a useful screen for PH. Estimating the exact prevalence of PH across
echocardiographic PASP is definitely challenging because of the different thresholds used to
define PH. In our cohort, using a cutoff at PASP>36 mmHg, PH was present in a significant
proportion of our HCM population (36%), with moderate or severe in a small proportion
(6%). The prevalence of PH was concordant with other left-side heart diseases such as aortic
stenosis and heart failure with preserved ejection fraction which share similar haemodynamic
features with HCM[3, 4].
In clinical practice, the impairment of diastolic function and left atrial dilation has been
regarded as primary risk factors of PH in left-side heart disease[3]. Consistent with previous
reports, our findings showed that the left atrium was significantly enlarged in PH-HCM
patients compared with in no PH-HCM patients. Additionally, diastolic function, assessed by
E/A and E/e’ ratio, was also significantly decreased in PH-HCM patients compared with in
HCM patients. As in other left-heart diseases [3] or heart failure with preserved ejection frac-
tion [19], PH appear to be the consequence of the increase of LV filling pressure, due to an
impaired relaxation and augmented stiffness of the myocardium. HCM is a potentially inher-
ited cardiomyopathy characterized by hypertrophy in the absence of another etiology. Some
investigators have attributed diastolic dysfunction or mitral regurgitation to slow early ventric-
ular filling associated with increased dependence on late diastolic filling by atrial contraction,
thereby favoring the development of PH [20]. In the long-term, the PASP increase drives a
Table 4. Regression: Correlation with the PASP.
Univariable analysis Multivariable analysis
β-coefficient p-value β-coefficient p-value
Global stress MBF -0.23 0.030
Global MFR -0.32 0.002 -0.35 0.001
Minimal CVR -0.17 0.111
SBP 0.14 0.213 0.29 0.006
DBP 0.13 0.216
LAD 0.27 0.011
E/A ratio 0.31 0.003 0.35 0.001




PASP:pulmonary artery systolic pressures; MBF: myocardial blood flow;MFR: myocardial flow reserve; CVR: coronary vascular resistance; SBP: systolic blood pressure;
DBP: diastolic blood pressure; LAD: left atrial diameter. BMI: body mass index; Multivariate regression model adjusted for minimal CVR,SBP,DBP, age, BMI and
smoker, only independent variables that attained p< 0.05 are listed. E/A:ratio of peak early diastolic velocity(E)/peak atrial filling velocity(A); E/e’: ratio of peak early
diastolic velocity (E) /peak early diastolic velocity of the septal mitral annulus (e’).
https://doi.org/10.1371/journal.pone.0212573.t004
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progressive pulsatile loading of right ventricle, subsequently leading to right ventricle failure
[21].
The concept of microvascular dysfunction as a precursor of HCM has been tested in
multiple prior studies [7, 22]. It seems to be the result of structural changes in small vessels by
luminal narrowing of the intramural microvascular network caused by hyperplasia and hyper-
trophy of the intima and media. Evidences have been showed that measurement of hyperemia
MBF and MFR by means of PET is the most effective way to assess microvascular dysfunction
in vivo [22]. A novel observation regards the role of microvascular dysfunction in PH in our
HCM cohort. Global stress MBF and MFR values were generally depressed, whereas minimal
CVR were elevated in PH-HCM patients compared with no PH-HCM patients. Based on pre-
vious studies [23, 24], MBF� 1.8 mL/min/g or MFR� 2.5 are used as a cutoff to distinguish
abnormal or normal myocardial hyperemic flow increases, the number of patients with
blunted stress MBF/MFR was much higher in PH-HCM patients. As intracoronary resistance
relates inversely not only to the vessel diameter but also to the velocity of the blood flow [25].
Mechanistically, It was probably explained by the process that higher LV afterload and lower
microvascular density in HCM patients may increase metabolic demand whereas reduce
hyperemic flow, and thus myocardial perfusion, which in turn causes diastolic dysfunction
resulting in increased left atrial pressure and thus pulmonary artery wedge pressure [26].
On the other hand, we found that the extent of global MFR were most negatively related to
the severity of PASP, and the correlations were not improved in regional analysis, suggesting
that the increased PASP in patients with HCM are not limited to microvascular dysfunction
localized to certain walls but a diffuse process. In addition to traditional risk factors, including
age, BMI, smoker, blood pressure, LA size and diastolic function, the global MFR was signifi-
cantly associated with the PASP. Further multivariate linear regression analyses showed that
global MFR, E/A ratio and SBP were independent predictive factors for PH in HCM patients.
The progression of PH involves complex mechanisms including hemodynamic changes and
cardiac function [27]. The potential for biomarker combinations is currently of considerable
interest in the prediction of PH in HCM patients, and our study suggests that a combination
of impaired global MFR, diastolic dysfunction and elevated blood pressure might be helpful
for the screening and identification of PH in HCM patients.
In addition to MBF quantifications, we assessed LV function by means of gated PET and
found the occurrence of abnormal LVEF reserve was in nearly a half of 89 HCM patients, con-
sistent with two recent reports[16, 28]. Moreover, we showed a trend towards LVEF decrease
after stress and blunted LVEF reserve, which appeared to be greater in those subjects with PH.
The mechanism underling transient LV dysfunction has been partially elucidated by Dr. Galla-
gher [29] that vasodilator-induced redistribution of blood flow from the maximally vasodilated
subendocardial layers to the subepicardial layers, resulting in ischemia. Since our study has
excluded significant epicardial coronary stenosis, ischemia induced by microvascular dysfunc-
tion appears to play a role in the genesis of PH in HCM patients.
Of note, although LVOT obstruction is an established risk factor for adverse outcome in
HCM patients, the effect of relief of LVOT obstruction after septal reduction therapy on PH
was still paradoxical [4, 20]. Our data did not recognize an association between HCM pheno-
type (LVOT obstruction) and PASP or microvascular function. When taken in conjunction
with our univariate and multivariate regression results, it appears that microvascular dysfunc-
tion could be a more powerful risk factor for PH-HCM.
There are some limitations of our study must be considered. Firstly, this was a retrospective
study enrolled form a unique center. Secondly, assessment of pulmonary hemodynamics was
derived from Doppler echocardiography but not the right heart catheterization, pulmonary
pressure estimated from tricuspid regurgitation cannot distinguish whether the increase in
PET-measured myocardial flow reserve and echocardiography-estimated pulmonary artery systolic pressure
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pulmonary pressure is just a passive backward transmission of filling pressures driven by left
ventricular diastolic dysfunction or secondary mitral regurgitation, atrial arrhythmias, or if
there is also a superimposed component of pulmonary vasoconstriction due to progressive vas-
cular remodeling, thereby limiting the accuracy of evaluation for PH. Finally, we are lacking
complete data on other possible contributors to PH, such as RV function, RV MBF/MFR
which could be of value for better understanding of pathophysiology in PH-HCM.
Conclusion
Our study demonstrated that elevated PASP correlated with microvascular dysfunction in
HCM patients. Global MFR was suggested to be an independent predictor for PH. Further-
more, global MFR, especially combined with diastolic dysfunction and elevated blood pressure
demonstrated a better predictive value for PH-HCM. Our study may introduce a novel con-
cept of a link between these two unfavorable disease features.
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